Wockhardt’s Zaynich NDA gets USFDA acceptance: What India’s first NCE means for the company

Wockhardt

The US drug regulator has just handed Wockhardt a milestone moment, and Indian pharma a rare innovation story.

The US Food and Drug Administration (USFDA) has accepted a New Drug Application (NDA) for Wockhardt Ltd.’s novel antibiotic, Zaynich, marking the first-ever NDA acceptance for a new chemical entity (NCE) from an Indian pharma company. For the Mumbai-based drugmaker, it is more than a regulatory step; it is a global credibility marker.

The NDA is accepted only when the application is 'proper and full', Chairman Habil Khorakiwala told Moneycontrol, calling the move a significant validation of the company’s science and documentation.

The road to US approval and commercialisation

Wockhardt is targeting a US approval for Zaynich by mid-2026. The review window is relatively tight, with Khorakiwala expecting the process to take “six to eight months”.

“We are very confident of a positive outcome,” he said.

The next critical steps involve a rigorous on-site evaluation by the USFDA, including visits to manufacturing facilities, document inspections and process checks. Zaynich is manufactured in Europe at USFDA-compliant facilities, a fact Wockhardt believes will help smooth this phase.

In parallel, the company has already started preparing for commercialisation.

“We have started commercialisation work and are considering several options,” Khorakiwala said. These range from going solo in the US market to tying up with partners for marketing and distribution.

Beyond the US, Wockhardt has applied for approval with India’s regulator and is planning launches in Europe and emerging markets in the second half of FY26.

Zaynich: an antidote for superbugs

Zaynich is a novel antibiotic aimed at treating severe multi-drug resistant infections — the kind of “superbug” cases that are increasingly hard to treat with existing drugs.

In global Phase III trials, Zaynich delivered a 20 percent higher cure rate than Meropenem, a widely used carbapenem antibiotic for serious bacterial infections.

For Wockhardt, a potential USFDA nod would cap a 25-year pursuit in novel antibiotics. The company spends about Rs 200 crore annually on R&D and employs 145 scientists, including 50 PhDs, underlining the scale of its long-term bet on anti-infectives.

Substantial revenue potential

The market opportunity for Zaynich is substantial, according to the company’s estimates. “If Zaynich gets an FDA nod, the market potential is substantial,” Khorakiwala stated.

A lot has been riding on the approval of Zaynich for Wockhardt. The drugmaker estimates an addressable patient pool of approximately 2 million patients globally in select markets. The company sees a $7 billion opportunity in the US and European markets alone, targeting roughly 371,000 carbapenem-resistant cases. China accounts for another 657,000 potential patients.

The potential business in the home market is also significant. Wockhardt estimates the Indian market, which has around 1.1 million cases, could translate to a potential annual business of Rs 17,000 crore. This combined market potential positions Zaynich as a potential game-changer for the company's financial future.